Skip to main content

Security report for kemwellbiopharma.com

Kemwell Pharma · Healthcare · India

High risk. 8 critical or high findings in GDPR outside view, Email security and 2 other checks.

Security score

46/100

Risk levelHigh

0–100, higher is better. How it is calculated

Kemwell Pharma is a biologics contract development and manufacturing organization (CDMO) based in India, providing integrated services including biologics development, cGMP manufacturing, quality control, and analytical development. The company positions itself as one of Asia's best and India's largest biologics CDMOs, serving global pharmaceutical and biotech organizations with a focus on mammalian cell-culture based protein therapeutics. The website reflects a mature digital presence with detailed service descriptions, downloadable brochures, and multiple contact forms equipped with anti-bot measures. Technically, the site is built on WordPress with modern plugins and integrations such as Gravity Forms, Cloudinary for media, and Google Analytics for tracking. Security posture is good with HTTPS, security headers, and captcha protections, though privacy compliance could be improved with a visible cookie consent mechanism and more comprehensive privacy and security policies. Overall, the site is professional, trustworthy, and well-structured, supporting the company's market position and business model.

Scanned

NIS2 and GDPR posture

GDPR outside view
28/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

8 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • Critical

      No HTTPS encryption

      GDPR requires appropriate security measures for personal data

      What to do: Implement SSL/TLS certificate for HTTPS

  2. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • Critical

      No HTTPS Encryption

      Website does not use HTTPS encryption, making all data transmission vulnerable to interception

      What to do: Implement SSL/TLS certificate and redirect all HTTP traffic to HTTPS

  4. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

Need hands-on remediation? Email guard@offseq.com

Keep watching kemwellbiopharma.com

This scan found 23 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
0
Security headers
15
Email security
60
DNS health
75
Network security
100
GDPR outside view
28
Average
46

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Kemwell Pharma operates in the healthcare and manufacturing sectors, targeting biopharmaceutical companies requiring contract development and manufacturing services for biologics. Their business model focuses on providing end-to-end solutions from process development to commercial batch manufacturing, supported by regulatory licenses and multiple audits by industry experts. The company leverages partnerships and technological support from a leading German biopharmaceutical company, enhancing its competitive advantage. The website's content and structure indicate a medium-sized enterprise with a strong regional presence and growing global reach. The presence of multiple downloadable brochures and detailed service pages suggests a focus on lead generation and client engagement. The company maintains a consistent brand image and demonstrates trust through certifications and audit disclosures.

Security posture

The website demonstrates a good security posture with enforced HTTPS, use of Cloudflare Turnstile Captcha on forms to prevent automated abuse, and inferred presence of security headers such as Content-Security-Policy and X-Frame-Options. No exposed sensitive data or vulnerable libraries were detected in the HTML content. However, the absence of a published security policy, incident response information, or vulnerability disclosure reduces transparency. Privacy compliance is limited by the lack of a cookie consent mechanism and detailed GDPR compliance statements. Overall, the site is secure for typical business operations but could enhance user trust and regulatory compliance by publishing more comprehensive security and privacy documentation.

Recommendations

  1. Implement a visible and comprehensive cookie consent banner to comply with GDPR and other privacy regulations.
  2. Publish a dedicated security policy and incident response plan accessible from the website footer or legal section.
  3. Add a vulnerability disclosure policy or security.txt file to encourage responsible reporting of security issues.
  4. Enhance accessibility features to improve compliance with WCAG standards and broaden user inclusivity.
  5. Regularly audit and update third-party libraries and plugins to mitigate potential vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Kemwell Pharma
Description
Kemwell Biopharma provides customized process, product development & manufacturing solutions to biopharmaceutical organizations worldwide
Key services
Biologics Development, Biologics cGMP Manufacturing, Quality Control and Quality Assurance, Integrated Services, Process Development, Formulation Development, Analytical Development
Content quality
good
Branding
consistent

Technology

Stack
WordPress, Gravity Forms, jQuery, Cloudinary, Google Analytics, Google Tag Manager, Cloudflare Turnstile Captcha, Owl Carousel
Frameworks
Yoast SEO
Platforms
WordPress
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • Use of HTTPS
  • Use of Cloudflare Turnstile Captcha for forms
  • No exposed sensitive data in HTML
  • Use of security headers (inferred)

Analytics and tracking

Services
Google Analytics, Google Tag Manager, LeadFeeder
Tracking level
moderate
Privacy practices
basic

Advertising

Tracking pixels
LeadFeeder
Marketing tools
LeadFeeder
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a professional CDMO service provider in biologics with integrated development and manufacturing
  2. Multiple detailed service offerings with downloadable brochures via forms
  3. Use of modern web technologies and SEO optimization
  4. No visible security or privacy policy pages beyond basic privacy policy
  5. No visible cookie consent mechanism
  6. Multiple contact forms with anti-bot measures (Turnstile Captcha)
  7. No visible security.txt or vulnerability disclosure
  8. No explicit incident response or security policy information
Technical notes

Notes

The website is built on WordPress CMS with a modern tech stack including Gravity Forms for form management, Cloudinary for media optimization, and Google Analytics and Tag Manager for analytics. The site uses lazy loading and resource prefetching to optimize performance, with responsive design elements for mobile optimization. The presence of multiple JavaScript libraries and plugins indicates a feature-rich site, though performance is moderate likely due to the number of scripts and external calls. The site is hosted behind Cloudflare, providing CDN and security benefits. Technical SEO is well addressed with proper meta tags, Open Graph data, and structured JSON-LD schema. There is room for improvement in accessibility and privacy compliance features.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with kemwellbiopharma.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review kemwellbiopharma.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.